At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,343 enrolled
Drug / intervention
GSK2340274A +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
In Brief
A Phase 2 clinical trial evaluating GSK2340274A, GSK2340273A, and 1 other intervention for Influenza. Completed, enrolled 1,343 participants across 14 sites in 2 countries.
Detailed Summary
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older. This protocol posting has been updated for sections impacted by the Protocol amendment 1, Sept 2009.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionNov 2009
Study CompletionDec 2010
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartOct 11, 2009
Primary CompletionNov 9, 2009
Study CompletionDec 16, 2010
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 16.8 years ago
Interventions
GSK2340274Abiological
one or two intramuscular injections
GSK2340273Abiological
one or two intramuscular injections
Saline placebobiological
One injection